BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31786983)

  • 1. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
    Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
    Hypertension; 2020 Jan; 75(1):51-58. PubMed ID: 31786983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
    Kario K; Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
    Am J Hypertens; 2021 May; 34(5):540-551. PubMed ID: 33165570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
    Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
    J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
    Rakugi H; Ito S; Itoh H; Okuda Y; Yamakawa S
    Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
    Ichikawa S; Tsutsumi J; Sugimoto K; Yamakawa S
    Adv Ther; 2022 Oct; 39(10):4779-4791. PubMed ID: 35976603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
    Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
    Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
    Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of esaxerenone (CS-3150) in primary hypertension: a meta-analysis.
    Sun R; Li Y; Lv L; Zhang W; Guo X
    J Hum Hypertens; 2024 Feb; 38(2):102-109. PubMed ID: 38177694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
    Yamakawa S; Homma T; Yamada M; Igawa Y; Yoshimura M
    Nihon Yakurigaku Zasshi; 2020; 155(5):340-350. PubMed ID: 32879177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
    Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
    Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study.
    Katsuya T; Inobe Y; Uchiyama K; Nishikawa T; Hirano K; Kato M; Fukui T; Hatta T; Iwasaki A; Ishii H; Sugiura T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T;
    Hypertens Res; 2024 Apr; 47(4):835-848. PubMed ID: 38212366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
    Arai K; Morikawa Y; Ubukata N; Sugimoto K
    Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
    Wan N; Rahman A; Nishiyama A
    J Hum Hypertens; 2021 Feb; 35(2):148-156. PubMed ID: 32661269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
    Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
    Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
    Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
    Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study.
    Yamamoto E; Usuku H; Sueta D; Suzuki S; Nakamura T; Matsui K; Matsushita K; Iwasaki T; Sakaino N; Sakanashi T; Hirayama K; Kurokawa H; Kikuta K; Yamamoto N; Sato K; Tokitsu T; Taguchi T; Shiosakai K; Sugimoto K; Tsujita K;
    Adv Ther; 2024 Mar; 41(3):1284-1303. PubMed ID: 38310194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
    Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study.
    Sung KC; Oh YS; Cha DH; Hong SJ; Won KH; Yoo KD; Rha SW; Ahn YK; Ahn JC; Jang JY; Hong TJ; Cho SK; Park SH; Hyon MS; Nam CW; Chae IH; Yoo BS; Song JM; Jeong JO; Yoon YW; Kim BS; Yang TH; Cho DK; Kim SH; Choi YJ; Ahn JH; Jeon DW; Kim HS
    Clin Ther; 2018 Jan; 40(1):50-63.e3. PubMed ID: 29248384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.